FDA clears Baxter’s prepackaged synthetic bone filler graft | Digital Science

Baxter International received an clearance for a new formulation of its Actifuse substitute, now deliverable via a syringe that requires no mixing or preparation.

For use in a variety of orthopedic surgeries, Actifuse Flow uses the same silicate-substitution technology to help accelerate bone formation after being placed in small voids or gaps in the skeletal system.

The latest addition to Baxter’s osteobiologics portfolio, it is designed to maintain a flowable consistency throughout surgery. As the graft is resorbed, it is replaced by the patient’s own bone during the healing process.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!



Booking.com

In a statement, Baxter said it expects Actifuse Flow to be used in open and less-invasive surgeries in the pelvis, extremities and posterolateral spine, and described it as being well-suited to fill small bone defects and complex geometries.

The Deerfield, Illinois-based company expects Actifuse Flow to be available to U.S. customers by the end of the year, in 5 mL, 3 mL and 1.5 mL sizes. The graft substitute is intended only as a for gaps and voids, and not where it will serve as structural or load-bearing support.

You might also like More from author

Comments are closed.